EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Loss of histone deubiquitinase Bap1 triggers anti-tumor immunity

Hong Chang, Mingxia Li, Linlin Zhang, Meng Li, Swee Hoe Ong, Zhiwei Zhang, Jie Zheng, Xiang Xu, Yu Zhang, Jing Wang, Xingjie Liu, Kairui Li und 6 weitere

Cellular Oncology · 2025

DOI: 10.1007/s13402-024-00978-y ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cellular Oncology, 2025. Verfasst von Hong Chang und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Tongji Hospital, Frontier Science Center for Stem Cell Research, School of Life Sciences and Technology, Tongji University,…. Hauptthemen laut MEDLINE: Ubiquitin Thiolesterase, Tumor Suppressor Proteins, Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Immunotherapy using PD-L1 blockade is effective in only a small group of cancer patients, and resistance is common. This emphasizes the importance of understanding the mechanisms of cancer immune evasion and resistance. METHODS: A genome-scale CRISPR-Cas9 screen identified Bap1 as a regulator of PD-L1 expression. To measure tumor size and survival, tumor cells were subcutaneously injected into both syngeneic WT mice and immunocompromised mice. The phenotypic and transcriptional characteristics of Bap1-deleted tumors were examined using flow cytometry, RNA-seq, and CUT&Tag-seq analysis. RESULTS: We found that loss of histone deubiquitinase Bap1 in cancer cells activates a cDC1-CD8+ T cell-dependent anti-tumor immunity. The absence of Bap1 leads to an increase in genes associated with anti-tumor immune response and a decrease in genes related to immune evasion. As a result, the tumor microenvironment becomes inflamed, with more cDC1 cells and effector CD8+ T cells, but fewer neutrophils and regulatory T cells. We also found that the elimination of Bap1-deleted tumors depends on the tumor MHCI molecule and Fas-mediated CD8+ T cell cytotoxicity. Our analysis of TCGA data further supports these findings, showing a reverse correlation between BAP1 expression and mRNA signatures of activated DCs and T-cell cytotoxicity in various human cancers. CONCLUSION: The histone deubiquitinase Bap1 could be used as a biomarker for tumor stratification and as a potential therapeutic target for cancer immunotherapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ubiquitin ThiolesteraseTumor Suppressor ProteinsNeoplasmsAnimalsHumansCell Line, TumorMiceB7-H1 AntigenTumor MicroenvironmentMice, Inbred C57BLCD8-Positive T-LymphocytesGene Expression Regulation, Neoplastic

Stichwörter der Autor:innen

Anti-tumor immunityBap1PD-L1Tumor microenvironment

Substanzen

Ubiquitin ThiolesteraseTumor Suppressor ProteinsB7-H1 AntigenBAP1 protein, mouseBAP1 protein, human

Autor:innen und Institutionen

  • Department of Hematology, Tongji Hospital, Frontier Science Center for Stem Cell Research, School of Life Sciences and Technology, Tongji University, 1239 Siping Road, Shanghai, 200092, China.
  • Wellcome Sanger Institute, Hinxton, Cambridge, CB10 1HH, UK.
  • Translational Research Institute of Brain and Brain-Like Intelligence, Department of Anesthesiology, Shanghai Fourth People's Hospital Affiliated to Tongji University School of Medicine, Shanghai, 200081, China.
  • GMU-GIBH Joint School of Life Sciences, The Guangdong-Hong Kong-Macau Joint Laboratory for Cell Fate Regulation and Diseases, Guangzhou Laboratory, Guangzhou Medical University, Guangzhou, China.
  • Department of Biology, Southern University of Science and Technology, 1088 Xueyuan Avenue, Shenzhen, 518055, China.
  • Department of Hematology, The First Affiliated Hospital of Xiamen University and Institute of Hematology, School of Medicine, Xiamen University, Xiamen, China. zhajie@xmu.edu.cn.

Förderung

  • National Key Research and Development Program of China
  • National Natural Science Foundation of China

Zitieren

APA

Chang, H., Li, M., Zhang, L., Li, M., Ong, S. H., Zhang, Z., Zheng, J., Xu, X., Zhang, Y., Wang, J., Liu, X., Li, K., Luo, Y., Wang, H., Miao, Z., Chen, X., Zha, J., & Yu, Y. (2025). Loss of histone deubiquitinase Bap1 triggers anti-tumor immunity. Cellular Oncology. https://doi.org/10.1007/s13402-024-00978-y

Vancouver

Chang H, Li M, Zhang L, Li M, Ong SH, Zhang Z, et al. Loss of histone deubiquitinase Bap1 triggers anti-tumor immunity. Cellular Oncology. 2025. doi:10.1007/s13402-024-00978-y

BibTeX
@article{Chang2025,
  author = {Chang, Hong and Li, Mingxia and Zhang, Linlin and Li, Meng and Ong, Swee Hoe and Zhang, Zhiwei and Zheng, Jie and Xu, Xiang and Zhang, Yu and Wang, Jing and Liu, Xingjie and Li, Kairui and Luo, Yao and Wang, Haiyun and Miao, Zhichao and Chen, Xi and Zha, Jie and Yu, Yong},
  title = {Loss of histone deubiquitinase Bap1 triggers anti-tumor immunity},
  journal = {Cellular Oncology},
  year = {2025},
  doi = {10.1007/s13402-024-00978-y}
}
Kostenlos starten →